Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-64042056 · 1 trial · 1 indication
Change from baseline in brain tau burden, as measured by tau PET (including but not limited to Braak I-VI ROIs, tau naive composite ROI, Connection Rank ROI, and New Tau Composite ROI Volume) will be reported.
| Arm | Type | Description |
|---|---|---|
| Arm A: JNJ-64042056 | EXPERIMENTAL | Participants will receive intramuscular (IM) injection of JNJ-64042056 from Week 0 up to a maximum of Week 76. |
| Arm B: Placebo | PLACEBO_COMPARATOR | Participants will receive IM injection of placebo from Week 0 up to a maximum of Week 76. |
| Name | Type | Description |
|---|---|---|
| JNJ-64042056 | DRUG | JNJ-64042056 will be administered intramuscularly. |
| Placebo | DRUG | Placebo will be administered intramuscularly. |
Inclusion Criteria: * Elevated brain tau pathology defined as Braak 3 region of interest standardized uptake value ratio (ROI SUVR) greater than (\>) 1.1 (or equivalent based on emerging data) on a screening tau PET scan, reviewed centrally by a qualified reader to enrich for probability of disease...
Top 20 of 24 competitors
JNJ-64042056 is an investigational small molecule being developed for Alzheimer's disease. It is currently in Phase 2 clinical development for the treatment of preclinical Alzheimer's disease, meaning it is being studied in participants who have not yet developed symptoms but may be at risk for the condition.
JNJ-64042056 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is currently conducting a Phase 2 clinical trial of this investigational drug for Alzheimer's disease.
JNJ-64042056 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The current Phase 2 trial is active but not recruiting participants.
JNJ-64042056 is being studied in a Phase 2 clinical trial with the identifier NCT06544616. This randomized, double-blind, placebo-controlled study is evaluating the drug in 55 participants with preclinical Alzheimer's disease across multiple countries, including the United States, Australia, Belgium, France, Germany, Japan, Spain, Sweden, and the United Kingdom.
No alternative names for JNJ-64042056 have been disclosed. The drug is identified solely by its development code JNJ-64042056 in the clinical trial registry. It is an investigational small molecule being studied for Alzheimer's disease.